Risk factor
Very poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of BIO3.DE is 37 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell